Endurance Technologies IPO Launches Key Details on Rs 1162 Crore Public Offering Greeces Q1 2026 Budget Surplus Soars Past Expectations to 5175 Billion Dime Community DCOM Gains 166 Support Holds at 3491 20260514 2026 CNBC Disruptor 50 AI Companies Dominate as New Leader Emerges Ascentage Pharma AAPG Surges 445 Testing Resistance at 2169 Meta Plans 6065 Billion AI Infrastructure Investment Signaling IndustryWide Spending Surge The Pitfalls of Chasing Returns Why LongTerm Discipline Matters in Investing Kenya Fuel Price Protests Turn Deadly as Economic Strain Boils Over Fed Rate Hike Odds Rising Prediction Markets Point to July 2027 Increase Charter Communications Revises Offer for Liberty Broadband in Enhanced Buyout Agreement US Consumer Sentiment Hits Record Low in May as Iran Conflict Fuels Inflation Concerns AnheuserBusch InBev Shares Decline After Sales Miss Expectations Qualcomms Stock Surge Reflects Growing Investor Confidence in AI Device Boom Trump Asks Supreme Court to Halt TikTok Ban Adding Uncertainty to Platforms Future ALOY Q1 2024 Earnings EPS Misses Estimates Significantly Stock Rises Unexpectedly CRWV Q1 2026 Earnings WiderthanExpected Loss Weighs on Shares Dream Finders Homes Inc DFH Q1 2026 Earnings EPS Miss and Stock Decline Amid Housing Market Headwinds AIM ImmunoTech Q1 2026 Earnings WiderthanExpected Loss on Absence of Revenue Nicolet Bankshares NIC Q1 2026 Earnings Significant EPS Miss of 697 as Bank Faces Headwinds EZRA Q1 2023 Earnings Massive EPS Surprise of 324 Against Negative Estimate Revenue Unreported THRY Q1 2026 Earnings Profitability Surprise Drives Stock Higher Scholastic Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline PEBO Q1 2026 Earnings EPS Slightly Misses Consensus as Shares Rise 116 MongoDB Inc MDB Q1 2026 Earnings EPS Beat Drives Positive Stock Reaction PPIH Q1 2026 Earnings Strong EPS Beat Drives Investor Attention Despite Mild Stock Decline Wealthy Couple Pretends to Be Strapped for Cash to Fit In The Social Cost of Financial Disguise PHGE Q4 2025 Earnings Severe EPS Miss as BiomX Continues Clinical Development